Investigational Drug Information for IMR-687
✉ Email this page to a colleague
What is the drug development status for IMR-687?
IMR-687 is an investigational drug.
There have been 6 clinical trials for IMR-687.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 13th 2020.
The most common disease conditions in clinical trials are Anemia, Sickle Cell, Thalassemia, and Heart Failure. The leading clinical trial sponsors are Imara, Inc., Quintiles, Inc., and [disabled in preview].
Summary for IMR-687
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 18 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2020-08-13) |
| Vendors | 16 |
Recent Clinical Trials for IMR-687
| Title | Sponsor | Phase |
|---|---|---|
| Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction | Imara, Inc. | Phase 2 |
| A Study of IMR-687 in Subjects With Beta Thalassemia | Imara, Inc. | Phase 2 |
| A Study of IMR-687 in Subjects With Sickle Cell Disease | Imara, Inc. | Phase 2 |
Clinical Trial Summary for IMR-687
Top disease conditions for IMR-687
Top clinical trial sponsors for IMR-687
US Patents for IMR-687
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
